4'-Chlorodeschloroalprazolam is a triazolobenzodiazepine derivative which has been sold as a designer drug, presumably with sedative effects, first identified in Australia and the US in 2021,[1][2] and subsequently in Ireland.[3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H13ClN4 |
Molar mass | 308.77 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Trigg S, Wells JM, McGann J, Bock S, Holman A, Harrison SM, et al. (September 2022). "The alprazolam analogue 4'-chloro deschloroalprazolam identified in seized capsules". Drug Testing and Analysis. 14 (9): 1672–1680. doi:10.1002/dta.3325. PMID 35666014.
- ^ Reber JD, Rodgers C, Ayala JL, Miller J, Stout P, Lee D (November 2023). "Interference of the novel designer benzodiazepine 4'-chloro-deschloroalprazolam with alprazolam analysis in toxicology and seized drug DUID casework". Journal of Analytical Toxicology. 47 (8): 680–684. doi:10.1093/jat/bkad047. PMID 37530763.
- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.